CJC-1295 and sermorelin are both growth-hormone-releasing hormone (GHRH) analogs: each prompts the pituitary to release the body's own growth hormone rather than replacing it. The main difference is timing. Sermorelin is a short-acting GHRH (1-29) analog, while CJC-1295 is engineered to last longer. This comparison is about that mechanism and their very different approval histories, not a ranking.
Reviewed for accuracy · Last reviewed July 8, 2026At a high level both act the same way: as GHRH analogs they nudge the pituitary to release its own growth hormone, so effects tend to build gradually and taper once the compound is stopped. The practical contrast is duration. Sermorelin is short-acting and was dosed daily (usually at night to match the overnight GH pulse), whereas CJC-1295 with DAC carries an albumin-binding complex that extends its half-life to several days, so it is dosed only about weekly.
The regulatory histories differ. Sermorelin was approved decades ago as Geref for diagnostic testing and pediatric growth-hormone deficiency, then discontinued commercially, generally described as a business decision rather than a safety or efficacy withdrawal. The sermorelin people encounter today is typically compounded off-label. CJC-1295 has never been FDA-approved, and its substantial human data is limited to a small early-phase pharmacokinetic study of the with-DAC form.
Neither of these is a basis for choosing one on your own. Which, if either, is appropriate is a medical decision, and compounded or independently sourced products carry none of the purity or accuracy testing a regulated finished-drug product does.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.